Clin Osteol 2008; 13(2): 49-56

Clinical manifestations of paraneoplastic syndromes in the musculoskeletal systemReview articles

P. Horák, V. Vavrdová

The authors deal with clinical manifestations of paraneoplastic syndromes affecting the musculoskeletal system. These syndromes may develop in the course of cancer but they may also precede it. According to established criteria by A. Fam, paraneoplastic rheumatic syndromes are classified as follows: articular, muscular, dermal and mixed. These syndromes include hypertrophic osteorthropathy, carcinoma polyarthritis, amyloid arthropathy, dermatomyosistis, paraneoplastic vasculitis, algodystrophic and antiphospholipid syn­ dromes, relapsing polychondritis, oncogenic osteomalacia and polymyalgia rheumatica. Numerous less known entities also have to be considered in certain situations, such as multicentric histiocytosis, RS3PE syndrome and Lambert-Eaton myasthenic syndrome. Can­ cer may also be accompanied by fasciitis, panniculitis, neutrophilic dermatosis, Raynaud's syndrome even with digital gangrene, erythromelalgia and lupus-like syndrome. The list of paraneoplastic syndromes is not complete and is being added to.

Keywords: Musculoskeletal system, paraneoplastic syndromes, clinical picture, diagnosis, treatment

Published: December 11, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Vavrdová V. Clinical manifestations of paraneoplastic syndromes in the musculoskeletal system. Osteologický bulletin. 2008;13(2):49-56.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Butler RC, Thompson JM, Keat ACS. Paraneoplastic rheumatic disorders: a re­ view. J R Soc Med 1987;80:168-72. Go to original source...
    2. Brooks PM. Rheumatic manifestations of neoplasia. Curr Opin Rheum 1992;40:90-3.
    3. Seda H, Alarcón GS. Musculoskeletal syndromes associated with malignancies. Curr Opin Rheum 1995;7:48-53.
    4. Avina-Zubieta JA, Enkerlin HL, Galindo-Rodriguez G. Rheumatic manifestations of malignancy. Curr. Opin. Rheum 1996;8:47-51. Go to original source...
    5. Fam AG. Praneoplastic rheumatic syndromes. Bailliére's Clinical Rheumatology 2000;14:515-33. Go to original source...
    6. Naschitz JE, Rosner I, Rozenbaum M et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 1999;29:43-55. Go to original source...
    7. Mičeková D, Lukáč J. Artropatie pri nádoroch. In: Rovenský J, Pvelka K, eds. Klinická reumatológia. 1. vyd. Martin, Vydavatelstvo Osveta, 2000:657-64.
    8. Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthritis Rheum 1988;18: 77-87. Go to original source...
    9. Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 1997;24:360-72.
    10. Abu-Shakra M, Buskila D, Conrad K et al. Cancer and autoimmunity: autoimmu­ ne and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60: 433 40. Go to original source...
    11. Schumacher HR Jr. Articular manifestations of hypertrophic pulmonary osteo­ arthropathy in bronchogenic carcinoma. Arthritis Rheum 1976;3:629-35. Go to original source...
    12. Rothschild BM, Rothschild CH. Recognition of hypertrofic osteoarthropathy in skeletal remains. J Rheumatol 1998;25:2221-7.
    13. Silveira LH., Lavín MM., Pineda C et al. Vascular endothelial growth factor and hypertrofic osteoarthropathy. Clin Exp Rheumatol 2000;18:57-62.
    14. Bradley JD, Pinals RS. Carcinoma polyarthritis: role of immune complexes in pa­ thogenesis. J Rheumatol 1983;5:826-8.
    15. Menon N, Madhok R. Symmetrical polyarthritis is not always rheumatoid. Ann Rheum Dis 1994;53:631-2. Go to original source...
    16. Falk RA, Comenzo MD, Skiner M. The systemic amyloidosis. N Engl J Med 1997;13:898-907. Go to original source...
    17. Ščudla V. Postižení pohybového systému u mnohočetného myelomu. In. Rovenský J et al. Reumatológia v teórii a praxi VI. Osveta, Martin 2004,582-638.
    18. Sigurgeirsson B, Lindelof BL, Edhag O et al. Risk of cancer in patients with der­ matomyositis or polymyositis. N Engl J Med 1992;326:363-7. Go to original source...
    19. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21:1855-9.
    20. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with der­ matomyositis: a population based study. J Rheumatol 1995;22:1300-3.
    21. Whitmore SE, Watson R, Rosenshein NB et al. Dermatomyositis sine myositis: association with malignancy. J Rheumatol 1996;23:101-5.
    22. Till SH, Jones AC. Dermatomyositis-how far to go! Ann Rheum Dis 1998;57: 198-200. Go to original source...
    23. Maoz CR, Langevitz P, Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998;27:319-24. Go to original source...
    24. Yazici Y, Kagen LJ. The association of malignancy with myositis. Curr Opin Rheumatol 2000;12:498-500. Go to original source...
    25. Lennon VA, Kryzer TJ, Griesmann, GE et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-74. Go to original source...
    26. Pfinsgraff J, Buckingham RB, Killian PJ et al. Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome. Semin Arthritis Rheum 1986;2:118-25. Go to original source...
    27. Virshup AM., Sliwinski AJ. Polyarthritis and subcutaneous nodules associated with carcinoma of the pancreas. Arthritis Rheum 1973;3:388-91. Go to original source...
    28. Thomson GTD, Keystone EC, Sturgeon JFG, Fornasier V. Erythema nodosum and non-Hodgkin_s lymphoma. J Rheumatol 1990;17:383-85.
    29. Lear JT, Atherton MT, Byrne JPH. Neutrophilic dermatoses: pyoderma gangre­ nosum and Sweet_s syndrome. Postgrad Med J 1997;73:65-8. Go to original source...
    30. Sourbier MJ, Dubost JJ, Sauvezie BJM and French study Group on POEMS Syn­ drome. POEMS syndrome: a study of 25 cases and review of the literature. Amer. J. Med. 1994;97:543-53. Go to original source...
    31. Sánchez-Guerrero J, Gutiérrez-Urena S, Vidaller A et al. Vasculitis as a paraneo­ plastic syndrome: report of 11 cases and review of the literature. J Rheumatol 1990;17:1458-62.
    32. Mertz LE, Conn DL. Vasculitis associated with malignancy. Curr Opin Rheum 1992;4:39-46.
    33. Pertuiset E, Lioté F, Launay-Russ E et al. Adult Henoch-Schonlein purpura asso­ ciated with malignancy. Semin Arthritis Rheum 2000;6:360-7. Go to original source...
    34. Cengiz M, Altundag MK, Zorlu AF et al. Malignancy in Bechcet's disease: a re­ port of 13 cases and a review of the literature. Clin. Rheumatol 2001;20:239-44. Go to original source...
    35. Petri M, Fye KH. Digital necrosis: a paraneoplastic syndrome. J Rheumatol 1985;4:800-1.
    36. Ameratunga R, Daly M, Caughey DE. Metastatic malignancy associated with re­ flex sympathetic dystrophy. J Rheumatol 1989;3:406-7.
    37. Johnson JJ, Leonard-Segal A, Nashel DJ. Jaccoud's type arthropathy: an associa­ tion with malignancy. J Rheumatol 1989; 9:1278-80.
    38. Saif MW, Hopkins JL, Gore SD et al. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myolomonocytic leukaemia. Leuk Lym­ phoma 2002;43:2083-92 Go to original source...
    39. Chub-Hsiung C, Chih-Hsuh C, Horng-An C et al. Multicentric histiocytosis pre­ senting with destructive polyarthritis, laryngopharyngeal dysfunction, and huge reticulohistiocytoma. J Clin Rheumatology 2006;12:252-4. Go to original source...
    40. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalatia: clinical characterization of a novel renal phosphate wasting disorder. J Clin Endocrinol Metab 1997;82:674-81. Go to original source...
    41. Silve C, Beck L. Is FGF23 the long sought phosphaturic factor phosphatonin? Nephrol Dial Transplant 2002;17:958-61. Go to original source...
    42. Schuck O. Poruchy metabolizmu fosforu. In: Schuck O ed. Poruchy metabolizmu vody a elektrolytů v klinické praxi. Grada Publishing s. r. o. 2000:197-205.
    43. Wilkins GE, Granleese S, Hegele RG et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor, J Clin Endocrinol Metab 1995;80:1628-34. Go to original source...
    44. Haga HJ, Eide GE, Brun J, Johansen A, Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteriitis. J Rheumatol 1993;20:1335-9.
    45. Olivo D, Mattace R. Concurrence of benign edematous polysynovitis in the elder­ ly (RS3PE syndrome) and endometrial adenocarcinoma. Scand J Rheumatol 1997;26:67-8. Go to original source...
    46. Russel E. Remitting seronegative symmetrical synovitis with pitting edema syn­ drome: follow-up for neoplasia. J Rheumatol 2005;32:1760-7.
    47. Fietta P, Manganelli P. Remitting seronegative symmetrical synovitis with pitting edema syndrome: follow-up for neoplasia. To the editor. J Rheumatol 2006;33: 2365-6.
    48. Rovenský J, Švancarová Ľ. Klinická a laboratórne prejavy paraneoplastických re­ umatických syndrómov. Rheumatologia 2007;21:117-124. Go to original source...
    49. Goméz-Puerta JA, Cervera R, Espinosa G. Antiphospholipid antibodies associa­ ted with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35:322-32. Go to original source...
    50. Miesbach W, Asherson RA, Cervera R et al. The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome Clin Rheumatol 2007;26:2109-14. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.